
    
      First- and second-phase decay rates of plasma HIV-1 RNA and changes in the intracellular
      levels of HIV-1 proviral DNA and LTR circles will be measured in subjects starting salvage
      antiretroviral therapy including raltegravir in Spain.
    
  